Dynavax Technologies started the dosing of patients for its phase 1B dose escalation clinical trial on its DV281 in patients with non-small cell lung cancer.
Dynavax Technologies (NASDAQ:DVAX) started the dosing of patients for its phase 1B dose escalation clinical trial on its DV281 in patients with non-small cell lung cancer.
As quoted in the press release:
This multi-center, open label trial is designed to evaluate safety and identify the optimal dose for a potential expansion phase of the study. The dose escalation study is expected to enroll approximately 24 patients in 5 cohorts with advanced NSCLC that has progressed on previous therapy. Dynavax engineered DV281 specifically for inhalation to facilitate local administration of a TLR9 agonist to lung tumors which are not easily accessible for intratumoral injection. NSCLC is the third tumor type, in addition to melanoma and squamous cell carcinoma of the head and neck, where Dynavax is studying aTLR9 agonist in combination with an anti-PD-1 therapy.